Edition:
United States

Kura Oncology Inc (KURA.OQ)

KURA.OQ on NASDAQ Stock Exchange Global Select Market

13.85USD
3:59pm EST
Change (% chg)

$-1.05 (-7.05%)
Prev Close
$14.90
Open
$15.05
Day's High
$15.30
Day's Low
$13.60
Volume
76,917
Avg. Vol
150,197
52-wk High
$17.40
52-wk Low
$5.40

Chart for

About

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood... (more)

Overall

Beta: --
Market Cap(Mil.): $450.21
Shares Outstanding(Mil.): 30.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing‍​

* Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​ Source text:(http://bit.ly/2yNnKBA) Further company coverage:

Nov 09 2017

BRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and Co

* Kura Oncology Inc - on Nov 9, 2017, co entered into amendment to its sales agreement, dated January 27, 2017 with Cowen and Company LLC ‍​-SEC filing

Nov 09 2017

BRIEF-Kura Oncology reports third quarter 2017 financial results

* Kura Oncology reports third quarter 2017 financial results and provides corporate update

Nov 07 2017

BRIEF-KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL

* KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE

Oct 27 2017

BRIEF-Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

* Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

Sep 07 2017

BRIEF-‍Great Point Partners LLC reports 5.92 percent passive stake ​in Kura Oncology Inc

* ‍Great Point Partners LLC reports 5.92 percent passive stake ​in Kura Oncology Inc as on August 11, 2017 - sec filing Source text: (http://bit.ly/2vXMuCE) Further company coverage:

Aug 21 2017

BRIEF-Kura Oncology prices public offering of 7.70 mln common shares at $6.50 per share

* Kura oncology announces pricing of public offering of common stock

Aug 10 2017

BRIEF-Kura Oncology announces commencement of public offering of common stock

* Kura Oncology announces commencement of public offering of common stock

Aug 09 2017

BRIEF-Kura Oncology Q2 loss per share $0.40

* Kura Oncology reports second quarter 2017 financial results and provides update on Tipifarnib phase 2 study

Aug 07 2017

BRIEF-Kura Oncology ‍enters into collaboration agreement with Foundation Medicine ​

* Kura Oncology Inc - ‍entered into a collaboration agreement with Foundation Medicine, Inc.​

Jul 13 2017

Earnings vs. Estimates